Drug Approval | April 28, 2024
Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal
The USFDA has issued 5 observations pursuant to the completion of audit
The USFDA has issued 5 observations pursuant to the completion of audit
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
With the receipt of the EIR, the inspection stands successfully closed.
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Subscribe To Our Newsletter & Stay Updated
